177948-33-3

Basic information

• Product Name: Methyl 2-AMino-2-(1-Boc-4-piperidyl)acetate
• Synonyms: Methyl 2-AMino-2-(1-Boc-4-piperidyl)acetate;tert-Butyl 4-(1-amino-2-methoxy-2-oxoethyl)
• CAS NO: 177948-33-3
• Molecular Formula: C₁₃H₂₄N₂O₄
• Molecular Weight: 272
• Mol File: 177948-33-3.mol

Chemical Properties

• Boiling Point: 350.7±12.0 °C(Predicted)
• Appearance: /
• Density: 1.116±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 7.36±0.50(Predicted)
• CAS DataBase Reference: Methyl 2-AMino-2-(1-Boc-4-piperidyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-AMino-2-(1-Boc-4-piperidyl)acetate(177948-33-3)
• EPA Substance Registry System: Methyl 2-AMino-2-(1-Boc-4-piperidyl)acetate(177948-33-3)

Safety Data

• Hazardous Substances Data: 177948-33-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-amino-2-(1-Boc-4-piperidyl)acetate is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into complex molecular structures, particularly those targeting the central nervous system. Its presence in the molecular structure can contribute to the development of drugs with specific therapeutic effects.
Used in Medical Research:
In the field of medical research, Methyl 2-amino-2-(1-Boc-4-piperidyl)acetate serves as a valuable building block for the creation of new compounds with potential medicinal properties. Its unique structure allows researchers to explore its interactions with biological targets and its potential role in the development of novel therapeutic agents.
Used in Organic Chemical Synthesis:
Methyl 2-amino-2-(1-Boc-4-piperidyl)acetate is used as a building block in organic chemical synthesis, where its functional groups and Boc-protected nitrogen atom enable the formation of a wide range of chemical products. This versatility makes it an important component in the synthesis of various organic compounds for different applications.

Upstream product

• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 100945-15-1 N-(benzyloxycarbonyl)phosphonoglycine trimethyl ester 
• 881016-88-2 4-(bromo-methoxycarbonyl-methyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1380344-28-4 tert-butyl 4-(1-azido-2-methoxy-2-oxoethyl)piperidine-1-carboxylate 
• 175213-46-4 1-t-Butoxycarbonyl-4-(methoxycarbonylmethyl)piperidine 
• 313491-20-2 4-(benzyloxycarbonylamino-methoxycarbonyl-methylene)-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 357413-57-1 (4'-methoxy-biphenyl-4-sulfonylamino)-[1-(2-methoxy-ethoxycarbonyl)-piperidin-4-yl]-acetic acid methyl ester 
• 1380344-31-9 C₂₁H₃₀N₄O 

Relevant articles and documents

Preparation method of 2-amino-2-(1-methyl-4-piperidyl)ethanol

The invention discloses a preparation method of 2-amino-2-(1-methyl-4-piperidyl) ethanol. The preparation method comprises the following steps: reacting 2-methyl-2-propyl-4-(1-amino-2-methoxy-2-oxoethyl)-1-piperidinecarboxylate (a compound II) with benzyl bromide under the action of an alkali 1 to generate a compound III; dissolving the compound III in an organic solvent, and generating a compound IV under the action of a reducing agent; and removing benzyl from the compound IV under the action of a catalyst/hydrogen to generate a compound I.

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin- associated disorders, such as Frontotemperal lobe dementia (FTLD).

Compound, pharmaceutically acceptable salt thereof and medical application thereof

The invention belongs to the field of medicines, and particularly relates to a compound shown as a formula I or medicinal salt thereof. The invention also relates to application of the compound or themedicinal salt thereof in selectively inhibiting LF activity, resisting anthrax toxin toxicity and preventing or treating anthracnose.

4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, R4, X, Y, and Z are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

The discovery of novel cyclohexylamide CCR2 antagonists

As a result of further SAR studies on a piperidinyl piperidine scaffold, we report the discovery of compound 44, a potent, orally bioavailable CCR2 antagonist. While having some in vitro hERG activity, this molecule was clean in an in vivo model of QT pro

Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases

A novel series of carboxylic acids containing a substituted piperidine were synthesized and tested for inhibition of selected matrix metalloproteinases. Multiple analogues prepared based on this novel design were found to inhibit the target MMPs (MMP-2,-3

Azetidine, pyrrolidine and piperidine derivatives

A class of substituted azetidine, pyrrolidine and piperidine derivatives are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1Dα receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1Dα receptor subtype relative to the 5-HT1Dβ subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.